Biomedicines (May 2023)

Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience

  • Carolin Kubelt,
  • Dana Hellmold,
  • Eva Peschke,
  • Margarethe Hauck,
  • Olga Will,
  • Fabian Schütt,
  • Ralph Lucius,
  • Rainer Adelung,
  • Regina Scherließ,
  • Jan-Bernd Hövener,
  • Olav Jansen,
  • Michael Synowitz,
  • Janka Held-Feindt

DOI
https://doi.org/10.3390/biomedicines11061518
Journal volume & issue
Vol. 11, no. 6
p. 1518

Abstract

Read online

Local drug delivery systems (LDDS) represent a promising therapy strategy concerning the most common and malignant primary brain tumor glioblastoma (GBM). Nevertheless, to date, only a few systems have been clinically applied, and their success is very limited. Still, numerous new LDDS approaches are currently being developed. Here, (partial resection) GBM animal models play a key role, as such models are needed to evaluate the therapy prior to any human application. However, such models are complex to establish, and only a few reports detail the process. Here, we report our results of establishing a partial resection glioma model in rats suitable for evaluating LDDS. C6-bearing Wistar rats and U87MG-spheroids- and patient-derived glioma stem-like cells-bearing athymic rats underwent tumor resection followed by the implantation of an exemplary LDDS. Inoculation, tumor growth, residual tumor tissue, and GBM recurrence were reliably imaged using high-resolution Magnetic Resonance Imaging. The release from an exemplary LDDS was verified in vitro and in vivo using Fluorescence Molecular Tomography. The presented GBM partial resection model appears to be well suited to determine the efficiency of LDDS. By sharing our expertise, we intend to provide a powerful tool for the future testing of these very promising systems, paving their way into clinical application.

Keywords